<SEC-DOCUMENT>0001193125-26-006994.txt : 20260108
<SEC-HEADER>0001193125-26-006994.hdr.sgml : 20260108
<ACCEPTANCE-DATETIME>20260108070749
ACCESSION NUMBER:		0001193125-26-006994
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260108
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260108
DATE AS OF CHANGE:		20260108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Climb Bio, Inc.
		CENTRAL INDEX KEY:			0001768446
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				832273741
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40708
		FILM NUMBER:		26517342

	BUSINESS ADDRESS:	
		STREET 1:		20 WILLIAM STREET
		STREET 2:		SUITE 145
		CITY:			WELLESLEY HILLS
		STATE:			MA
		ZIP:			02481
		BUSINESS PHONE:		1-866-857-2596

	MAIL ADDRESS:	
		STREET 1:		20 WILLIAM STREET
		STREET 2:		SUITE 145
		CITY:			WELLESLEY HILLS
		STATE:			MA
		ZIP:			02481

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eliem Therapeutics, Inc.
		DATE OF NAME CHANGE:	20190219
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d92848d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:clym="http://climbbio.com/20260108" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-373">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-01-08_to_2026-01-08">0001768446</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="clym-20260108.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-01-08_to_2026-01-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-08</xbrli:startDate> <xbrli:endDate>2026-01-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-384">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt:datemonthdayyearen" id="ixv-385">January&#160;8, 2026</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-386">CLIMB BIO, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:stateprovnameen" id="ixv-387">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-388">001-40708</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-389">83-2273741</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-390">20 William Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-391">Suite 145</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-392">Wellesley Hills</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:stateprovnameen" id="ixv-393">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-394">02481</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-395">(866)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-396">857-2596</ix:nonNumeric></span></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:boolballotbox" id="ixv-397">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:boolballotbox" id="ixv-398">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:boolballotbox" id="ixv-399">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:boolballotbox" id="ixv-400">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-401">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-402">CLYM</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:exchnameen" id="ixv-403">The Nasdaq Stock Market LLC</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(The Nasdaq Global Market)</p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:boolballotbox" id="ixv-404">&#9746;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2026-01-08_to_2026-01-08" format="ixt-sec:boolballotbox" id="ixv-405">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2026, Climb Bio, Inc. (the &#8220;Company&#8221;) issued a press release announcing its pipeline progress and anticipated milestones for 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Corporate Updates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2026, the Company issued a press release announcing its pipeline progress and anticipated milestones for 2026, including the following pipeline updates: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In November 2025, the Company dosed the first patient in its PrisMN Phase 2 clinical trial of budoprutug in primary membranous nephropathy. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In December 2025, the Company received clearance of its investigational new drug application in China to initiate a separate, parallel Phase 1b clinical trial of budoprutug in systemic lupus erythematosus (&#8220;SLE&#8221;) in China (the &#8220;China SLE Trial&#8221;), which is designed to complement the Company&#8217;s ongoing global Phase 1b clinical trial of budoprutug in SLE and which will seek to enroll SLE patients who have lupus nephritis. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company has completed dosing of the first cohort in its Phase 1 clinical trial of the subcutaneous formulation of budoprutug in healthy volunteers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In December 2025, the Company completed dosing of the first cohort in its Phase 1 clinical trial of CLYM116 in healthy volunteers. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company announced the following anticipated milestones for 2026: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to announce initial data from its Phase 1 clinical trial of the subcutaneous formulation of budoprutug in healthy volunteers in the first half of 2026. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to dose the first patient in the China SLE Trial in the first half of 2026. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to announce initial data from the PrisMN Phase 2 clinical trial of budoprutug in the second half of 2026. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to announce initial data, including preliminary efficacy data, from its Phase 1b/2a clinical trial of budoprutug in immune thrombocytopenia in the second half of 2026. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to announce initial data, including preliminary efficacy data, from its global Phase 1b clinical trial of budoprutug in SLE in the second half of 2026. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects to announce initial data from its Phase 1 clinical trial of CLYM116 in healthy volunteers in <span style="white-space:nowrap">mid-2026.</span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Runway </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the Company&#8217;s current operating plan, the Company estimates that its cash, cash equivalents and marketable securities will be sufficient to fund its operations into 2028. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could exhaust its available capital resources sooner than it expects. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for the Company; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; the anticipated timelines for reporting initial data from the Company&#8217;s ongoing and planned clinical trials of budoprutug and CLYM116; the anticipated timeline for initiating the Company&#8217;s parallel Phase 1b clinical trial of budoprutug in patients with systemic lupus erythematosus in China and the projected enrollment of patients with systemic lupus erythematosus that have lupus nephritis; the anticipated benefits of the Company&#8217;s technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (&#8220;Mabworks&#8221;); the sufficiency of the Company&#8217;s cash resources for the period anticipated; and other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; &#8220;will,&#8221; &#8220;working&#8221; and similar expressions. Forward-looking statements are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of the Company to timely and successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Mabworks; changes in applicable laws or regulation; the possibility that the Company may be adversely affected by other economic, business and/or competitive factors; the Company&#8217;s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials and nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; the outcome of any legal proceedings or other disputes; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates the Company may develop. For a discussion of other risks and uncertainties and other important factors, any of which could cause the Company&#8217;s actual results to differ materially from those contained in the forward-looking statements, see the &#8220;Risk Factors&#8221; section, as well as discussions of potential risks, uncertainties and other important factors, in the Company&#8217;s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form <span style="white-space:nowrap">8-K</span> represent the Company&#8217;s views as of the date hereof and should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company&#8217;s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as required by law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d92848dex991.htm">Press release of Climb Bio, Inc., dated January&#160;8, 2026 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Climb Bio, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;8, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Aoife Brennan</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Aoife Brennan, M.B., Ch.B.</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">President and Chief Executive Officer</span></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d92848dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g92848g0108042339595.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>First patients dosed in CLYM116 Phase 1 healthy volunteer study </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Strong financial position with cash runway expected into 2028 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WELLESLEY HILLS, MASS., (GLOBE NEWSWIRE) &#8211; January&nbsp;8, 2026 &#8211; Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company
developing therapeutics for patients with immune-mediated diseases, today announced progress updates for its budoprutug and CLYM116 programs. The Company also highlighted its strategic priorities and key anticipated milestones for 2026 and refreshed
its financial guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Reflecting on 2025, we set out with ambitious goals, and I am proud of the substantial progress made across our clinical
development and corporate objectives,&#8221; said Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio. &#8220;We are now primed for a fulsome evaluation of budoprutug, our anti-CD19 monoclonal antibody, with the initiation
of four clinical trials and the clearance of our China IND. We also rapidly advanced CLYM116, our anti-APRIL monoclonal antibody, into the clinic and dosed our first subjects in less than one year after announcing the
<FONT STYLE="white-space:nowrap">in-licensing</FONT> transaction. Across the portfolio we achieved 20 regulatory clearances to conduct clinical trials and activated 45 trial sites globally, a testament to our robust clinical execution.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Looking ahead, 2026 is poised to be a transformative and data-rich year for Climb, with initial readouts expected from all our ongoing trials,&#8221;
continued Dr.&nbsp;Brennan. &#8220;With CLYM116 for IgAN, budoprutug in pMN, ITP, and SLE, and the potential to evaluate lupus nephritis in a separate, parallel China SLE trial, our pipeline has the potential to address the high unmet need which
exists across renal and other <FONT STYLE="white-space:nowrap">B-cell</FONT> mediated diseases. Together, the anticipated datasets from our ongoing studies will inform the next steps in our mission to deliver differentiated treatments for
immune-mediated diseases with substantial therapeutic and commercial potential.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2025 Major Accomplishments and Pipeline Status&#8195; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Budoprutug anti-CD19 monoclonal antibody </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiated Phase 2 Trial in Primary Membranous Nephropathy (pMN):</B> In November 2025, FPI was achieved in the
PrisMN Phase 2 trial. The study is designed to evaluate pharmacodynamics (including B cells, anti-PLA2R, and total immunoglobulin) and preliminary efficacy (including complete and partial remission) in pMN patients with persistent proteinuria
despite optimized RAAS inhibition, and to identify a dose to carry forward into Phase 3 clinical development. In November 2025, the Company also published budoprutug pMN Phase 1b long-term outcome data at the 2025 American Society of Nephrology
(ASN) Kidney Week that demonstrated long-term control of proteinuria. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiated Phase 1b/2a Trial in Immune Thrombocytopenia (ITP):</B> Dosing is ongoing in the open-label,
dose-escalation Phase 1b/2a clinical trial of budoprutug in relapsed/refractory ITP designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy, including B cell depletion and platelet counts. At the 2025
American Society of Hematology (ASH) conference in December, the Company presented a poster detailing the Phase 1b/2a trial design. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiated Global Phase 1b Trial in Systemic Lupus Erythematosus (SLE) and Received Regulatory Clearance of SLE
IND in China:</B> Dosing is ongoing in the global, open-label, dose-escalation Phase 1b trial of a single dose of budoprutug in moderate to severe SLE to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy,
including <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion, autoantibody levels, and clinical activity. In December 2025, the Company received clearance of its investigational new drug application (IND) in China to initiate a separate,
parallel China Phase 1b trial in SLE, which will complement our ongoing study and also seek to enroll SLE patients who have lupus nephritis. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiated Subcutaneous (SC) formulation Phase 1 Trial:</B> First cohorts were dosed in the Phase 1 trial in
healthy volunteers, which is designed to evaluate bioavailability, pharmacokinetics, and pharmacodynamics, including B cell depletion, of the subcutaneous formulation of budoprutug. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CLYM116 anti-APRIL monoclonal antibody </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Obtained Exclusive License to Develop and Commercialize CLYM116: </B>Entered into a technology transfer and
exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070, Mabworks) in January 2025 for the rights to develop and commercialize CLYM116 in the territory outside of Greater China.<B>&nbsp;</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Presented Preclinical Data: </B>Completed IND enabling studies and shared preclinical data highlighting the
unique &#8216;sweeper&#8217; mechanism and product profile at the 2025 ASN Kidney Week in November and reviewed the opportunity in IgAN at a CLYM116-focused R&amp;D Spotlight Webcast in September 2025.<B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiated Phase 1 Clinical Trial: </B>In December 2025, the Company achieved FPI and completed dosing of the
first cohort in the ongoing Phase 1 clinical trial in healthy volunteers to evaluate safety, pharmacokinetics, and pharmacodynamics.<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Regulatory Clearance of Mabworks IND in China: </B>In December 2025, our partner, Mabworks, received clearance
of its IND in China to initiate a Phase 1 trial. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Milestones and Cash Guidance </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expanded senior leadership team with appointments of Edgar D. Charles, M.D., MSc as Chief Medical Officer, Perrin
Wilson, Ph.D., as Chief Business Officer, Susan Altschuller, Ph.D., MBA as Chief Financial Officer, Adam Villa, MS, MBA as SVP, Technical Operations, and Ashley Jones as SVP, People&nbsp;&amp; Workforce Strategy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthened Board of Directors with the addition of industry veterans Kim Cobleigh Drapkin, CPA and Bo Cumbo.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Refreshed financial guidance, with cash, cash equivalents, and marketable securities expected to fund operations
into 2028. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2026 Anticipated Milestones </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Budoprutug: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>SC formulation Phase 1:</B> initial data from healthy volunteer study (H1 2026) <B></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>China SLE Phase 1b:</B> first patient dosed (H1 2026) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>PrisMN (pMN) Phase 2: </B>initial data (H2 2026) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ITP Phase 1b/2a</B>: initial data, including preliminary efficacy (H2 2026) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>SLE Phase 1b:</B> initial data, including preliminary efficacy (H2 2026) </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CLYM116 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 1:</B> initial data from healthy volunteer study <FONT STYLE="white-space:nowrap">(mid-2026)</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Climb Bio, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Climb Bio,
Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company&#8217;s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated <FONT
STYLE="white-space:nowrap">B-cell</FONT> depletion and has potential to treat a broad range of <FONT STYLE="white-space:nowrap">B-cell</FONT> mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For
more information, please visit <U>climbbio.com</U>.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Budoprutug </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Budoprutug is a clinical-stage, anti-CD19 monoclonal antibody being developed by Climb Bio to address a broad range of
<FONT STYLE="white-space:nowrap">B-cell</FONT> mediated, immune-driven diseases. Designed with enhanced effector function and low picomolar affinity, budoprutug targets and depletes CD19-expressing B cells, including plasma blasts that are key
sources of pathogenic autoantibodies. Budoprutug clinical development is underway for three lead indications&#8212;primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). Early clinical data
suggest budoprutug may offer durable <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion, rapid reductions in autoantibodies, and clinical remission in pMN. A subcutaneous formulation is also in clinical development to enable broader patient
access and potential home-based dosing. Budoprutug has been granted orphan drug designation by the FDA for the treatment of pMN. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CLYM116</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>CLYM116 is a clinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand), a key driver of pathogenic <FONT
STYLE="white-space:nowrap">B-cell</FONT> activity in autoimmune diseases. CLYM116 employs a novel <FONT STYLE="white-space:nowrap">pH-dependent</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">bind-and-release</FONT></FONT>
&#8216;sweeper&#8217; mechanism to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life. This differentiated design offers the potential for rapid, deep, and durable inhibition of
APRIL with a favorable safety profile and less frequent dosing. CLYM116 is being advanced for the treatment of IgA nephropathy (IgAN) and may also have broader utility across other <FONT STYLE="white-space:nowrap">B-cell</FONT> mediated diseases
where APRIL plays a critical role. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, including
without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; the anticipated timelines for
reporting initial data from Climb Bio&#8217;s ongoing and planned clinical trials of budoprutug and CLYM116; the anticipated timeline for initiating Climb Bio&#8217;s parallel Phase 1b clinical trial of budoprutug in patients with systemic lupus
erythematosus in China and the projected enrollment of patients with systemic lupus erythematosus that have lupus nephritis; the anticipated benefits of Climb Bio&#8217;s technology transfer and exclusive license agreement with Beijing Mabworks
Biotech Co., Ltd. (&#8220;Mabworks&#8221;); the sufficiency of Climb Bio&#8217;s cash resources for the period anticipated; and other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221;
&#8220;would,&#8221; &#8220;will,&#8221; &#8220;working&#8221; and similar expressions. Forward-looking statements are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and
successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Mabworks; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other
economic, business and/or competitive factors; Climb Bio&#8217;s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other
regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage
clinical trials and nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other
immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; the outcome of any legal proceedings or other disputes; managing expenses; and raising the
substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties and other important factors,
any of which could cause Climb Bio&#8217;s actual results to differ materially from those contained in the forward-looking statements, see the &#8220;Risk Factors&#8221; section, as well as discussions of potential risks, uncertainties and other
important factors, in Climb Bio&#8217;s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio&#8217;s views as of the date hereof and
should not be relied upon as representing Climb Bio&#8217;s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio&#8217;s views to change. However, while Climb Bio may
elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors and Media </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carlo Tanzi, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kendall Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ctanzi@kendallir.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>clym-20260108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/8/2026 4:34:42 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:clym="http://climbbio.com/20260108"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://climbbio.com/20260108"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clym-20260108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clym-20260108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>clym-20260108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/8/2026 4:34:42 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>clym-20260108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 1/8/2026 4:34:42 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="clym-20260108.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g92848g0108042339595.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g92848g0108042339595.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ 3,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)10 M%
M)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%
I)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 08, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001768446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  08,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CLIMB BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2273741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 William Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wellesley Hills<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">857-2596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLYM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d92848d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>clym-20260108.xsd</File>
    <File>clym-20260108_lab.xml</File>
    <File>clym-20260108_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d92848d8k.htm">d92848d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d92848d8k.htm": {
   "nsprefix": "clym",
   "nsuri": "http://climbbio.com/20260108",
   "dts": {
    "schema": {
     "local": [
      "clym-20260108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "clym-20260108_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clym-20260108_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d92848d8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-01-08_to_2026-01-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d92848d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-01-08_to_2026-01-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d92848d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://climbbio.com//20260108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-26-006994-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-006994-xbrl.zip
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M;5>L;H3)\@RW-_U9;ZZ:7>-^_@902P,$%     @ ^#@H7%9A5V^L!@  H4D
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M2P9,M-NX*.^X4EOZKPOENVCV-W;4GO\!4$L#!!0    ( /@X*%P;=_@IW@0
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MW.$!\\#R^HSY9QZ_Q2/_ %!+ P04    " #X."A<L5H<J^T8  "4H0  #0
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M,@G(;PZB'#/Y-"@2#LJ#AR%(>X^R06*0\S(2*#]0X-]30]  \'_8+!EQ5#P
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M;65Q)B-)M@I!W(Y"T5J0,(_@L97C5(4T,Q>Y."U^79QI#159Z_XT/TYNI^V
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M.3$N:'1M[5UK<QLWLOVN*OT'E%))254D+2EQ8DNRZE(B;7%7KRLJ\<W]!LZ
M).+A8#*8D<S\^CW=P+SXD)RL[53M<FMK99(S !KH/OU =^_)Q?W5Y>G)1;_;
M.]W>.KD?W%_V3_O_UW[]NG-P\L)]Q/<O_ /BY.RF]ZLX>W=^<WES]V;G_<7@
MOK\CAO>_7O;?[$0Z5NVITI-I=G1MTIF,=D[%]A;>/U=QIM+3D][@E^+A1QUF
MTZ-7G9<ZWA$RTI,8 ZAQML/3W!:/S60ZT7$[,\G1?I(="_]Y9++,S-Q78Q-G
M;:O_4$<'U>>QG.EH?G2O9\J*:_4H[LQ,8J;NY>#=]9N=E!:Y<WIR=MK_.-4C
MG0FB6)R\.#L]>7%[6EM ;?1#C+ZPGJ7E[)Q^%X]L<DRC@/!U="R_5ZPLX*VB
M7>"=&UR]$\.[\S<[D]>'KWYX-=D_V'^U_\/A]]^_?OGZ9>>W9$(OWK_9N;QY
M=^.VKKG\VKR\_L^U@<4RL8/GD9Z-Q)DVHAO')H\#O'"K$T7L(&Y3,TF5M4+&
MH1AFJ<S41 ?X6IM49QJ/CDTJ#O</?RPW?\VV_?@E5C\X?:M3FXE$8BUQ9D5H
MK J%CL4H#TV2YED^H<7:JVMQ.Y56B4.1I5I&]$AR==T2CSJ;X@-HP9>AS*10
M'Q,59!C%JL" ZJF,Q@6%@[^!PIZQ.IX($T\,_5V@C8DZ&+TXE!5A@_M;/J_B
MQ^J7X67_6,A@JM4#"$S5)(]D9M*Y""(E4XFSY_/$8V)PW:,WSJ<ZEG\3Y>O.
M]OSRUZN#@Q\+^L14R2B;SL6#B7*\K%)ALSR<_TVK[L:9#C2M&J<EF:?:J0ZF
MS$,+#)<J&9H<M(U3,P.,1N4QU\Z8CK(@F0@CJ?M[2 , 8'UB#):( UI_ M[,
MM(D=58&T4Y'F\:.<5U*DX\P0Z:^>6_-GP;?3]_W+RS[X]U=Q,;B\'+;$57<X
M[+3$[KO+F[.^N.Z_'[X?W/7WQ'??O#H\.#@6_Y!Q+M.Y@_U7+2?IQ8\E-K;$
M( XZ8O=:VE#^?L3GL=?"\0: 21U@*VPF)TJ,M,E4,(U-9":0*C-+9#S?W@HA
M;Y%)Z&"SJ4IEHG(PB0//DK\=9\QF.=3P3(5:TO:%VBIPN6V)S(385^DQ.A1)
M <UY A[S2*PQSAK6X>?ES';$_52)<[<T\)PU8@IU&I%*I?/""+8$^J0">AKK
M@Z(5>/[&PS@#93,3U_4 /9>J,98V5>'V%HU7,<PDUR'!3.=+*[I3.L+#_>,[
M-8[ B Y!:8$O(8(*V)X)")[;<SD;$1?G5DP,]J/%) SP->U9'@HSIE,3-A_A
MD&,6W'+S9S)40-34X-\F3TM^*,]\AK/E 0.3)H;V59C1;[2D!YPJKQ*,9J4.
M1=?HL1)GJ8JQ7>#<SAD8]WS*?VXQFPZ+L8#*:BSZ'U60TSCB9CS6 7 /*RU9
MMB/\%KS' E,E8O-(QPG.XK.28ISC[&=*J <9Y9+%&.]7W--B@HC@]GGOX+68
MF=@$D8E!/GTY,N'<PQGMCH,T&F5["\.,ZYOA%)!C(7JVTC9XDAYT6@8JIR-H
MM<23$!(=1F"W\$$ROWL^KJVJ>WLWN%R]+$8=-Q4M@6=V^H/>'K-BP7G2.5A2
M*1&=93:5V )8/7,L3\@Q8*^0-R^Y@*ZW-]?WI1$\U9EJVT0&Z@C;BR7OG()G
M(YQ%3$K[Y 4]?0KR96QE0)O3$5W'++0X\$,V-A%,KT=5J>7#_96:&:\8019)
M'F0K=Y8F>&"Q_.&E5_E 9[PWB<P(NF5.>(7/F62>Q&BT%ZD9Y;8VH'),A946
MO/G%,=OSZ:4Q'UAG0I^''HBUQ29I.C<L=Z2( -K+,;DGS/E\L*6*Y8,C[F8I
M6*=L2]U4:5UL1*%YW8X6DKF]A2T'?.1XO)=VG)KP(EI)&$U3X"Q-/YAT85O6
M@+@P-V&:.7B!BFJ5\I! :3A< 95>')6(\@20%*MD2@C,;"H!7(DD$&D)^AM%
M*O+"0S8;+]T)2%)8\+"1EN>089@JSX0$_B*/9T#$6(%*,'4PW=Y2'[7%7GEH
M \$L7Y ?4F#B63$X:P<JB@H!6%)G4$)FHFBH%B^BKE3H.('/WBBJ'TUA_3SJ
MB,Q9X@)^.U8?(<Z92GB3Z(V9MI8 #;2&V(<'+#G4X[%*>0]HE@SLD,U8\6(<
MZ*DUBM?Q4!W[:QK< _MLIE)O#_E-;@C/&C7WZG/(#APX4FKB2OX&ONL&9')$
MVDX=9>P%%)PPS&266RSLX/7+XZ_AKM'BSNK&R!.:Y&G?_<<_Z;H+"H9TSR 2
M?JBSF[M>_ZY]?G-YV;T=]H^*?SQ)P"*U.\(-\V9G?T><P]"\[?9Z@^MWY>?A
M;?>\^/Q^T+N_>+-SL+__[8Y;SQU8=!XI\4;L)+ 5VR-PX(>VCDFO'\D'HT/_
M8*]X^>6W%5'WO84?O_]V1_SB;71L2FFONRC,=]\<_/!ZU6L'"Z^MF* ^4/-9
M.IS&KWY[1?-PQ'K6^<2=)M89.(M"A:7K?E_XL7#I,<%<7*G9"/J 3+=KPDD#
M!($CN NLW3LBCH+9+J[- QY3J;?^WMX.Q*.TE;[%>*S:5\4)G+'LW$E < @C
M;!([;53B=#*5T$8!F#@&<;#J=W4<1$ J(-:9(!ADDQ+,?WO9/;SSL&\R(H5
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MB@WDYWF)3R[:$',54_%Z,=NS+SW[P @0V<8VM.'VT0K]R*71^UR&*@3>23.
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M?DMMRQK5>J/0(HL;_PS@0&?<[46%%(!>$,:*NUN^RR^;.NN=@ ;%3,$Z<A<
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M4$L! A0#%     @ ^#@H7+%:'*OM&   E*$   T              ( !6P\
M &0Y,C@T.&0X:RYH=&U02P$"% ,4    " #X."A<I74=IJ07   9:@  $
M            @ %S*   9#DR.#0X9&5X.3DQ+FAT;5!+!08     !0 % #X!
(  !%0      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d92848d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="clym-20260108.xsd" xlink:type="simple"/>
    <context id="duration_2026-01-08_to_2026-01-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <startDate>2026-01-08</startDate>
            <endDate>2026-01-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-373">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-01-08_to_2026-01-08"
      id="Hidden_dei_EntityCentralIndexKey">0001768446</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-384">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-385">2026-01-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-386">CLIMB BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-387">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-388">001-40708</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-389">83-2273741</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-390">20 William Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-391">Suite 145</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-392">Wellesley Hills</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-393">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-394">02481</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-395">(866)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-396">857-2596</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-397">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-398">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-399">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-400">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-401">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-402">CLYM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-403">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-404">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2026-01-08_to_2026-01-08" id="ixv-405">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
